Since introduction of the parent compound cephalothin in 1962, cephalosporins have been popular with physicians because of their relatively broad range of antibacterial activity and lack of serious toxicity. Ceftriaxone (Ro 13-9904), a 2-aminothiazolyl methoxyimino cephalosporin derivative, is one of several "thirdgeneration" cephalosporins developed in recent years. Included in this group are the currently marketed drugs cefotaxime (10) and moxalactam (13) , as well as the investigational agents cefoperazone (16) , ceftazidime (20) , cefmenoxime *(28), and ceftizoxime (12) . All possess excellent activity against many gram-positive and gramnegative bacteria, including a number of species not susceptible to earlier cephalosporins. Cefsulodin (25) , a related drug, has activity directed against Pseudomonas aeruginosa and Staphylococcus aureus.
The chemical manipulations that have resulted in the extension of antimicrobial activity have generally not resulted in substantial changes in pharmacokinetic properties. The serum halflives of cefotaxime and moxalactam are 1.25 h (14) and 2.73 h (30) , respectively, which do not differ substantially from the half-life of cefazolin, which is 1.8 h (3). In contrast, ceftriaxone, which is structurally somewhat similar to cefotaxime but has a triazine substituent at the 3 position on the nucleus (21) , has a serum half-life of 6.5 to 8.6 h (22, 26) . Thus, ceftriaxone has the longest half-life of any cephalosporin.
After examination of the in vitro susceptibility of a large number of clinical isolates of gramnegative bacilli to ceftriaxone, we undertook a clinical trial to evaluate the efficacy of ceftriaxone in the treatment of a variety of bacterial infections.
MATERIALS AND METHODS
In vitro studies. Sterile standardized ceftriaxone powder was provided by Hoffmann-La Roche Inc. Minimum inhibitory concentrations (MICs) were determined by a standard microdilution technique (2) . A total of 437 gram-negative aerobic bacillary isolates collected from clinical sources over the last 2 years were tested for susceptibility to ceftriaxone. We also tested six strains of Listeria monocytogenes and 15 strains of group B streptococci. MICs were also determined on all isolates identified in the study population. Species with MICs of s16 ,ug/ml were considered susceptible to ceftriaxone (criterion established by the manufacturer).
Clnical trial. The trial was designed as an open, noncomparative study of parenteral ceftriaxone in serious bacterial infections. Patients hospitalized at the University of Alabama Medical Center and at the Veterans Administration Medical Center, Birmingham, Ala., were available for treatment. House officers at these institutions identified potential subjects and notified one of the investigators, who then interviewed and examined the patients. If eligibility criteria were fulfilled, written informed consent was obtained, and the patient was enrolled. Any adult with suspected or proven serious bacterial infection of the blood stream, skin, soft tissue, bone, joint, genitourinary tract, gastrointestinal tract, or hepatobiliary tract was eligible for enrollment in the study, with the following exceptions: (i) minors under 18 years of age; (ii) patients with a history of hypersensitivity to beta-lactam antibiotics; (ii) patients with infections caused by bacteria presumed or proven resistant to ceftriaxone; (iv) patients receiving other effective antibiotic therapy; (v) patients at risk for lifethreatening Pseudomonas infections (e.g., patients with leukemia or granulocytopenia); (vi) patients with central nervous system infections; (vii) patients with severe renal insufficiency (serum creatinine greater than 5.0 mg/dl), and (viii) pregnant or lactating females.
For retention in the study, the etiological bacteria had to be isolated, identified, and proved susceptible to ceftriaxone by disk diffusion criteria (resistant <12 mm, intermediate 13 to 15 mm, sensitive >16 mm).
Ceftriaxone (supplied by Hoffmann-La Roche Inc., Nutley, N.J.) was administered by intravenous infusion (except in one patient, who also received the drug intramuscularly after hospital discharge). The standard dose of ceftriaxone was 1 g diluted in 50 ml of either normal saline or 5% dextrose in water and infused over 20 to 30 min. The dose was repeated every 12 h for a minimum of 5 days. No other antibacterial agents were administered concomitantly.
Aerobic and anaerobic blood cultures were obtained from each patient before initiation of therapy. In patients with pneumonia, expectorated sputum or nasotracheal aspirate was obtained for Gram stain and culture. In patients with urinary tract infections, urine was collected for microscopic analysis and quantitative culture. In patients with soft tissue or bone infections, inflammatory material was obtained for Gram stain and culture by surgical drainage or needle aspiration. Cultures were collected on all patients before therapy, after 48 h of therapy, and after completion of therapy.
All patients were closely monitored to determine bacteriological and clinical outcome. Bacteriological cure was defined as follows: for patients with bacteremia, a sterile blood culture; for patients with pneumonia, elimination of the etiological agent from sputum; for patients with soft tissue or bone infections, elimination of the etiological bacteria from wounds or drainage; for patients with urinary tract infections, a sterile urine culture (<1,000 colonies per ml).
The following criteria were used to define clinical cure: for patients with pneumonia, defervescence of fever and improvement of cough, dyspnea, and signs of consolidation together with radiographic improvement; for patients with soft tissue or bone infections, resolution or improvement of inflammation and healing of wounds (plus radiographic improvement of osteomyelitis); for patients with urinary tract infections, resolution of fever, costovertebral angle tenderness, dysuria, frequency, and urgency; for patients with bacteremia, resolution of signs and symptoms of sepsis.
Subjects were questioned and examined daily for evidence of drug toxicity. In a previous report from this laboratory, these gram-negative bacilli were tested for susceptibility to moxalactam, cefotaxime, cefamandole, cefoxitin, cefazolin, carbenicillin, ticarcillin, gentamicin, tobramycin, and amikacin (7) . The activity of ceftriaxone was quite similar to that of cefotaxime and moxalactam. Ceftriaxone was less active against E. cloacae, slightly more active against P. aeruginosa and A. calcoaceticus, and substantially more active against Citrobacter sp. than cefotaxime or moxalactam.
Ceftriaxone was only moderately active against the six Listeria isolates (MIC90 12.5 ,ug/ ml), but showed very good activity against the group B streptococci (MICgo 0.78 p1g/ml). Moxa- lactam, tested simultaneously against the same 15 group B streptococcal isolates, was significantly less active (MIC90 12.5 ,ug/ml).
Clinical trial. Between January and May 1981, 55 patients were treated with ceftriaxone. There were 30 males and 25 females with a mean age of 57 years (range 18 to 90 years). Duration of therapy ranged from 2 to 57 days, with a mean of 10 days. Of these 55 subjects, 30 had definite bacterial pathogens isolated and were followed for bacteriological and clinical outcome. Of the remaining group of 25 patients, 15 had no pathogen isolated, 7 subsequently received additional antibiotics (though none of these seven patients received additional antibiotics because of suspected ceftriaxone failure), and 3 were proven to have nonbacterial diseases. These 25 patients were evaluated only for drug tolerance and pharmacokinetics. Table 2 summarizes the outcome of 10 patients with pneumonia treated with ceftriaxone. Five patients had pneumococcal pneumonia (including one with bacteremia), and two had pneumonia due to other streptococci. Haemophilus influenzae, Klebsiella pneumoniae, and S. aureus were cultured from one patient each. Nine of the ten patients were cured bacteriologically and clinically. Patient 29, a young man with group C streptococcal pneumonia requiring ventilatory support, was improving with ceftriaxone therapy. The streptococcus had been cleared from his sputum, but he developed pulmonary superinfection with a resistant strain of A. calcoaceticus, requiring the addition of tobramycin.
Thirteen patients were treated for urinary tract infections, including three with bacteremic illness (Table 3) . Eleven patients had clinical signs and symptoms consistent with pyelonephritis (fever, costovertebral angle tenderness, and leukocytosis in addition to dysuria, frequency, and urgency). E. coli was isolated from the urine of nine patients, including all three patients with bacteremia. Two patients had urinary tract infections due to multiply resistant gram-negative bacilli (patient 22, S. marcescens; patient 36, Providencia stuartii) that were susceptible only to third-generation cephalosporins. Patient 40 had E. coli and enterococci isolated from her VOL. 22, 1982 Hematological abnormalities developed in 13 patients. Patient 13 had a leukocyte count of 7,800/mm3 at the start of therapy which fell to 3,100/mm3 by the completion of therapy 9 days later; no follow-up leukocyte count was available. Two patients (patients 12 and 26) had minor (2 s) prolongations of their prothrombin times, which reverted to normal despite continuation of ceftriaxone. Nine patients (16%) developed thrombocytosis with a mean peak platelet count of 546,000/mm3 (range 406,000 to 824,000/ mm3). All of these patients had platelet counts of less than 350,000/mm3 at the start of therapy, and none had a primary hematological disease. Unfortunately, post-therapy platelet counts were not available for most of these patients. An additional patient (patient 39, pneumonia and sickle cell anemia) had a platelet count of 495,000/mm3 on the 4th day of therapy which rose to 1,300,000/mm3 on day 8 and to 1,500,000/ mm3 on day 12 resistant strains reported (11, 23) . Ceftriaxone, cefotaxime, and moxalactam are only minimally active against P. aeruginosa, other Pseudomonas species, and Acinetobacter species (1, 8, 18, 23, 29) . Although ceftriaxone may prove useful for treating infections due to Pseudomonas sp. or Acinetobacter sp. after in vitro testing has demonstrated susceptibility, the incidence of resistant strains is too high to permit ceftriaxone to be used alone for initial therapy of infectious disorders caused by these bacteria. Cefoperazone (16) , ceftazidime (20) , and cefsulodin (25) may prove to be more effective antipseudomonal cephalosporins. Ceftriaxone, moxalactam, and cefotaxime have all proved to be extremely active against Salmonella species (6, 8) , Shigella species (1, 18), Neisseria meningititis (18), Neisseria gonorrheae (including penicillin-resistant strains) (24, 32) , and Haemophilus influenzae (including ampicillin-resistant strains) (19, 24) .
Although the third-generation cephalosporins have enhanced activity against gram-negative bacilli, their activity against gram-positive cocci is inferior to that of first-generation cephalosporins. The MIC90 of ceftriaxone and cefotaxime for S. aureus (penicillin G susceptible or resistant) are in the range of 3.1 to 6.3 ,ug/ml, whereas moxalactam is slightly less active (1, 8, 11, 18, 23) . All three of the drugs have been clinically effective in treating S. aureus infections, but none is as active against this bacterium as are 6 the penicillinase-resistant semisynthetic penicillins or the first-generation cephalosporins (8) .
All cephalosporins, including these newer agents, are inactive against methicillin-resistant S. aureus (29) . The susceptibility of Staphylococcus epidermidis to ceftriaxone is variable, but the overall activity is poor (18) . Ceftriaxone and cefotaxime are both very active against Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, and viridans group streptococci (1, 8, 11, 18, 23, 29) . Moxalactam, however, is significantly less active against streptococcal species, especially pneumococci and group B streptococci (8, 18) . All cephalosporins are inactive against Streptococcus faecalis (8, 18) . Ceftriaxone and cefotaxime are frequently inactive against Bacteroides fragilis, the anaerobe generally considered most resistant to beta-lactam antibiotics (1, 8, 18, 23) . Moxalactam, slightly more active against anaerobes than the other two drugs, has about the same level of activity against B. fragilis as cefoxitin (8, 18) .
To summarize, ceftriaxone, cefotaxime, and moxalactam are all very active against the Enterobacteriaceae, Neisseria species, and H. influenzae. Ceftriaxone and cefotaxime are more active than moxalactam against gram-positive pathogens, whereas moxalactam has slightly better antianaerobic activity. None of these three drugs is dependably active against P. aeruginosa, A. calcoaceticus, or enterococci.
Ceftriaxone's principal advantage over the other third-generation cephalosporins may be its prolonged serum half-life. In this study, peak plasma ceftriaxone levels on the 4th day of therapy averaged 119 ,ug/ml, as determined by a bioassay. Trough levels, drawn 12 h after the preceding dose, averaged 53 p,g/ml, emphasizing ceftriaxone's prolonged duration of action. When compared with HPLC, the bioassay technique may underestimate ceftriaxone plasma levels, particularly at the higher levels. Ceftriaxone is highly bound to human plasma proteins, requiring deproteinization of the samples with acetonitrile before analysis. Inadequate deproteinization could account for some of the low levels measured.
Ceftriaxone was very well tolerated in our study group of 55 patients. The adverse reactions most frequently noted (thrombocytosis, 16%; elevated hepatic enzymes, 16%; eosinophilia, 8%) were all asymptomatic laboratory abnormalities. Eosinophilia, elevated liver function tests, and thrombocytosis have been previously associated with the administration of third-generation cephalosporins. Eosinophilia has been reported in 4 to 11% of patients receiving moxalactam (13, 27) (13, 27) . Though thrombocytosis can be associated with the stress of infection, a clear temporal relationship between the onset of thrombocytosis and the initiation of ceftriaxone therapy was apparent in these cases. Thrombocytosis has also been reported in 7 of 36 patients (19%) receiving moxalactam (27) .
In the clinical study reported here, ceftriaxone was effective as a single agent in treating 30 patients with pneumonia, urinary tract infections, and soft tissue infections caused by a variety of bacterial pathogens. The four patients in this series with bacteremic illnesses responded well to ceftriaxone. We did not have the opportunity to treat any patients with intraabdominal or pelvic infections. The bacteriological and clinical cure rates of 93% achieved in this clinical trial are impressive, particularly since many of the patients treated had complex underlying medical problems. Although ceftriaxone would certainly not be considered the drug of choice for some of the infections treated in this series (e.g., pneumococcal pneumonia or E. coli urinary tract infection), we felt that it was important to establish the safety and efficacy of the drug in treating a wide variety of infectious disorders.
Investigators Because of its marginal activity against P. aeruginosa, ceftriaxone alone cannot be recommended as initial therapy in any patient in whom the risk of P. aeruginosa infection is great, such as the patient with granulocytopenia. Although the combination of a third-generation cephalosporin and an aminoglycoside may be effective in some patients with pseudomonal disease (R. Cleeland, W. Delorenzo, L. Gulow, and P. Russo, 21st ICAAC, abstr. no. 804), until more clinical data are available we recommend the combination of an aminoglycoside plus an antipseudomonal penicillin, such as carbenicillin or ticarcillin, for serious pseudomonal infections.
Although patients with central nervous system infections were excluded from this study, ceftriaxone may prove to be a valuable drug in bacterial meningitis. In therapy of murine meningitis due to S. pneumoniae or K. pneumoniae, ceftriaxone was superior to ampicillin or cefotaxime (4). Other investigators have confirmed the efficacy of ceftriaxone in the dog meningitis model (15) and documented effective levels of the drug in the cerebrospinal fluid of patients with meningitis (5). Though rigorous clinical assessment will be necessary, ceftriaxone appears to be a potentially effective agent for bacterial meningitis, particularly that due to gram-negative bacilli or ampicillin-resistant H. influenzae.
Insufficient data are currently available to indicate how effective ceftriaxone will be in patients with serious intravascular infections. We recommend that ceftriaxone not be routinely used to treat bacterial endocarditis, particularly endocarditis due to gram-positive species, until its efficacy has been documented.
Ceftriaxone has an in vitro spectrum of activity similar to the spectra of the currently available third-generation cephalosporins. However, with its substantially longer half-life, ceftriaxone appears to have a potentially significant therapeutic advantage over cefotaxime and moxalactam. The high degree of efficacy and low incidence of significant toxicity demonstrated in this study should encourage further clinical evaluation.
